Drug Profile
Research programme: monoclonal antibody therapeutics - Sanofi/Valneva
Alternative Names: monoclonal antibodies; monoclonal antibodies - sanofi/VivalisLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur; Vivalis
- Developer Sanofi; Valneva
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Bacterial-infections in France (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Viral-infections in France (Parenteral)
- 25 Feb 2014 Research is ongoing in France